Bill Few Associates Inc. Acquires 4,569 Shares of Stryker Corporation $SYK

Bill Few Associates Inc. grew its stake in Stryker Corporation (NYSE:SYK) by 183.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,058 shares of the medical technology company’s stock after purchasing an additional 4,569 shares during the period. Bill Few Associates Inc.’s holdings in Stryker were worth $2,222,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. grew its stake in shares of Stryker by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock valued at $11,917,396,000 after purchasing an additional 133,892 shares during the period. State Street Corp boosted its stake in Stryker by 2.1% in the 4th quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock valued at $5,374,731,000 after buying an additional 311,507 shares in the last quarter. Geode Capital Management LLC grew its position in Stryker by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock valued at $2,636,238,000 after acquiring an additional 69,851 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Stryker by 22.6% during the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after acquiring an additional 1,198,665 shares during the period. Finally, Norges Bank acquired a new stake in shares of Stryker during the 4th quarter worth about $1,822,272,000. Institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on SYK. Wall Street Zen cut shares of Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. JPMorgan Chase & Co. reduced their target price on Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Robert W. Baird set a $385.00 price target on Stryker in a report on Friday, May 1st. Wolfe Research set a $375.00 price objective on Stryker in a research report on Friday, July 31st. Finally, BMO Capital Markets assumed coverage on Stryker in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $386.28.

Stryker Trading Up 0.4%

SYK stock opened at $337.41 on Thursday. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $396.86. The company has a market cap of $129.42 billion, a P/E ratio of 34.97, a PEG ratio of 2.14 and a beta of 0.76. The business has a fifty day moving average of $318.85 and a 200-day moving average of $334.29.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the business earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities research analysts expect that Stryker Corporation will post 15.02 EPS for the current year.

Insider Transactions at Stryker

In other Stryker news, VP M Kathryn Fink sold 3,500 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.45, for a total value of $992,075.00. Following the transaction, the vice president directly owned 177 shares of the company’s stock, valued at approximately $50,170.65. This trade represents a 95.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. The trade was a 30.04% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 323,264 shares of company stock worth $100,659,489 in the last quarter. 4.60% of the stock is owned by company insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.